Loading...
ESSA Pharma Inc.
EPIX•NASDAQ
HealthcareBiotechnology
$1.67
$0.01(0.60%)
ESSA Pharma Inc. (EPIX) Stock Overview
Explore ESSA Pharma Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
0.00%
Profit Growth
$-0.50
↑ 100.00%
EPS Growth
$-0.50
↓ 6.67%
Operating Margin
0.00%
↑ 100.00%
ROE
-18.14%
↑ 100.00%
Dividend Yield
0.00%
Analyst Recommendations
Strong Buy
0
Buy
0
Hold
1
Sell
0
Strong Sell
0
Price Targets
Low$2.00
Average$11.33
High$17.00
Company Profile
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
CEO
Dr. David Ross Parkinson M.D.
Employees
35
Headquarters
999 West Broadway, Vancouver, BC
Founded
2015